Welichem Files its Annual Audited Financials for Year Ended May 31, 2007, and Announces its AGM/SGM Date
VANCOUVER, Sep. 27 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that the Company filed its annual audited financials and MD & A. The net loss for the three-month period ended May 31, 2007, was $689,791 (2006 - $754,920), or 1 cent per share (2006 - 3 cents per share). The net loss for the 1-year period ended May 31, 2007, was $3,201,151 (2006 - $2,378,867), or 5 cents per share (2006 - 8 cents per share). Detailed information is available on the SEDAR and Welichem websites (www.sedar.com and www.welichem.com).
The Company also announced that its Annual and Special General Meeting will be held at The Simon Fraser University, Diamond Alumni Centre, Room 2065, 515 West Hastings Street, Vancouver, British Columbia (SFU Downtown Campus), at 1:30 p.m., Pacific Daylight Time, on Monday, October 29, 2007. Detailed information is also available on the SEDAR and Welichem websites (www.sedar.com and www.welichem.com).
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
York Yingping Guo
President and Chief Executive Officer
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements. The Company thus seeks safe harbour.
For further information
York Yingping Guo, President and Chief Executive Officer, Tel.: (604) 432-1703, Email: yorkguo@welichem.com
Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: investors@welichem.com
--------------------------------------------------------------------------------
Source: Welichem Biotech Inc.
|
